Publications by authors named "V Cuchelkar"
Article Synopsis
- IMbrella A is a Phase III study that allowed patients from earlier atezolizumab trials, like IMpower133, to continue receiving treatment for extensive-stage small cell lung cancer (SCLC) with atezolizumab plus chemotherapy after the initial trials closed.
- In IMbrella A, 18 out of 26 eligible patients rolled over for further treatment, and results showed that median follow-up was 59.4 months with estimated three-, four-, and five-year overall survival rates of 16%, 13%, and 12%, respectively.
- The study reported that 16.7% of patients experienced serious adverse events, with only one grade two hypothyroidism noted,
Purpose: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) represents the standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). However, many patients are unable to tolerate R-CHOP and have inferior outcomes. This study aimed to develop a practical tool to help physicians identify patients with newly diagnosed DLBCL unlikely to tolerate a full course of R-CHOP.
View Article and Find Full Text PDFBackground: Systemic therapies for metastatic biliary tract cancers are few, and patients have a median overall survival of less than 1 year. MyPathway evaluates the activity of US Food and Drug Administration-approved therapies in non-indicated tumours with potentially actionable molecular alterations. In this study, we present an analysis of patients with metastatic biliary tract cancers with HER2 amplification, overexpression, or both treated with a dual anti-HER2 regimen, pertuzumab plus trastuzumab, from MyPathway.
View Article and Find Full Text PDFBackground: Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics.
View Article and Find Full Text PDFPertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
April 2019
Article Synopsis
- * The ongoing phase 2a study included 57 patients with HER2-amplified metastatic colorectal cancer; most had poor treatment outcomes, but 32% showed some level of tumor response (complete or partial).
- * Common side effects reported included diarrhea, fatigue, and nausea, with 37% of patients experiencing severe adverse effects (grade 3-4).